Interpace Biosciences, Inc. (IDXG)

Market Cap	3.25M
Revenue (ttm)	46.93M
Net Income (ttm)	6.24M
Shares Out	4.42M
EPS (ttm)	0.39
PE Ratio	1.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,017
Average Volume	15,348
Open	0.7004
Previous Close	0.7339
Day's Range	0.6200 - 0.7004
52-Week Range	0.4430 - 3.5400
Beta	0.64
RSI	31.94
Earnings Date	Apr 11, 2025

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy ri...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 111
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2024, Interpace Biosciences's revenue was $46.93 million, an increase of 17.21% compared to the previous year's $40.04 million. Earnings were $6.24 million, an increase of 219.24%.